Methods for treating apolipoprotein E4-associated disorders
AssigneeThe J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
InventorsYadong Huang, Yaisa Andrews-Zwilling
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method of increasing the functionality of a GABAergic interneuron in the hilus of the hippocampus of an individual having at least one apolipoprotein E4 (apoE4) allele. The method generally involves reducing tau levels in the interneuron.
Claims7
A method of increasing the functionality of a GABAergic interneuron in the hilus of the hippocampus of an individual having at least one apolipoprotein E4 (apoE4) allele, the method comprising administering to the individual a tau-specific interfering nucleic acid that binds to a tau target and reduces the level of a tau polypeptide in the GABAergic interneuron, wherein the tau target is a contiguous stretch of at least 10 nucleotides of 5596-5807 of SEQ ID NO:2, wherein the tau-specific interfering nucleic acid is coupled to a carrier molecule that provides targeted delivery of the tau-specific interfering nucleic acid to the GABAergic interneuron.
Dependencies are inferred from the claim text.